
HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
The company’s groundbreaking drug encapsulated immunoliposomes may represent a significant improvement over existing antibody drug conjugates HANGZHOU, China–(BUSINESS WIRE)–HighField Biopharmaceuticals (HighField Bio), a clinical stage […]












